Lv51
890 积分 2023-04-19 加入
Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events
27天前
已完结
The next generation of immunotherapies for lung cancers
2个月前
已完结
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
2个月前
已关闭
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
2个月前
已完结
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
2个月前
已完结
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
2个月前
已完结
自身免疫性视网膜病变的临床特征与研究进展
3个月前
已完结
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
3个月前
已完结
Risk of pituitary immune-related adverse events caused by immune checkpoint inhibitors:a systematic review and meta-analysis
3个月前
已关闭
Risk of pituitary immune-related adverse events caused by immune checkpoint inhibitors:a systematic review and meta-analysis
3个月前
已关闭
皖公网安备34019202002308
